

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/336653777>

Designing a multi-epitope vaccine for cross-protection against Shigella spp: An immunoinformatics and structural vaccinology study

Article in *Molecular Immunology* · October 2019

DOI: 10.1016/j.molimm.2019.09.018

CITATIONS

4

READS

846

6 authors, including:



Mokhtar Nosrati

University of Kurdistan

30 PUBLICATIONS 128 CITATIONS

[SEE PROFILE](#)



Jafar Amani

Baqiyatallah University of Medical Sciences, Tehran, Iran

214 PUBLICATIONS 1,416 CITATIONS

[SEE PROFILE](#)



Shahram Nazarian

Shahed University

84 PUBLICATIONS 462 CITATIONS

[SEE PROFILE](#)


Some of the authors of this publication are also working on these related projects:



nothing [View project](#)



Design and evaluation of chimeric gene construct in order to make a polytope DNA vaccine candidate against Human cytomegalovirus [View project](#)



Designing a multi-epitope vaccine for cross-protection against *Shigella* spp: An immunoinformatics and structural vaccinology study



Mokhtar Nosrati^a, Abbas Hajizadeh^{b,*}, Shahram Nazarian^b, Jafar Amani^c, Amir Namvar Vansofla^b, Yousof Tarverdizadeh^b

^a Department of Biotechnology, Faculty of Advanced Sciences and Technologies, University of Igbaran, Igbaran, Iran

^b Biology Research Center, Faculty of Basic Sciences, Iran Azad University, Tehran, Iran

^c Applied Microbiology Research Center, Systems Biology and Polymers Institute, Razi Hospital University of Medical Sciences, Tehran, Iran

ARTICLE INFO

Keywords:
Shigella
Vaccine
Immunoinformatics
Infectious disease
Computational methodology

ABSTRACT

Shigelllosis is a severe diarrhoeal disease with high mortality and morbidity rate. Until now, there is no approved vaccine against the disease. Therefore, the present study was planned to design a novel multi-epitope vaccine against *Shigella* spp., the causative agents of the disease based on the immunoinformatic tool. For this end, firstly seven conserved antigens of the bacteria, including IpaA, IpaB, IpaC, IpaD, OmpC, OmpF and VirG were selected. Then, linear B-cell epitope mapping of these proteins was carried out and top-ranked and shared epitopes were selected based on antigenicity, allergenicity, stability, toxicity and physicochemical properties for further analysis. In next step, T-cell derived T-cell epitopes were determined and appropriate epitopes were selected for incorporation into the final construct. Moreover, the selected epitopes and two mucosal adjuvants including CTAx and LTA-IC were joined using appropriate linkers. The three dimensional structure of the final construct was modeled and evaluated in term of estimated quality and presence of conformational B-cell epitopes. Furthermore, binding affinity of the proposed vaccine to MHC I and II molecules were evaluated through a molecular docking method using FlexX as well as the stability of the vaccine-MHC complex was monitored by molecular dynamics method using the NAMD graphical user interface embedded in visual molecular dynamics. Finally, to evaluate the immunogenicity of the designed protein, the protein was administered to BALB/c mice and the serum IgG was determined by ELISA. The results indicated that the proposed vaccine has high estimated quality and binding affinity to both MHC I and II molecules. Moreover, molecular dynamics studies confirmed that the vaccine-MHC docked complexes were stable during simulation time. Animal study showed that the proposed protein is able to evoke strong humoral immune response. In sum, the results suggested that the proposed candidate vaccine could be considered as a promising anti-shigelllosis vaccine.

1. Introduction

Shigelllosis is an intestinal infectious disease caused by the gram negative bacteria of *Shigella* spp. Despite the great efforts made in the field of prevention, diagnosis and treatment of shigellosis, the disease is still a significant public health problem, especially in developing countries. It is estimated that approximately 1.1 million deaths occur due to *Shigella* infection annually (Schroeder and Hillb, 2008). The genus *Shigella* has 4 species or subgroups (A, B, C, and D) and 43 serotypes that among them *S. dysenteriae*, *S. flexneri*, *S. boydii* and *S. sonnei* are able to cause the disease in human (Niyogi, 2005). Symptoms of shigellosis typically start 1–2 days after exposure and include diarrhea, abdominal pain, fever and tenesmus. Shigella transmission can occur

through direct person-to-person contact or via the contaminated food and water (Bonith, 1991). Depending on the severity of the disease, patient's condition, age and gender, various strategies are used for the treatment of shigellosis, from antibiotic therapy for the severe cases to consumption of fluids and rest in moderate ones (Steffen, 1990). Although, antibiotic therapy may be useful for severe cases of shigellosis and can reduce the duration of symptoms, but there are increasing antibiotic resistance among *Shigella* spp. so that antibiotic treatment frequently fails (Murray et al., 2017). Due to wide spread antibiotic resistance as well as costly, time-consuming and low effectiveness of antibiotic therapy, many efforts have been done to introduce effective vaccine against *Shigella* spp. (Kaminski and Oaks, 2000; Levine et al., 2007; Hajizadeh et al., 2016). However, despite many efforts on the

*Corresponding author.

E-mail address: abbashajizadeh@gmail.com (A. Hajizadeh).